FPMI (FluoroPharma Medical) Days Payable: 0.00 (As of Dec. 2016)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is FluoroPharma Medical Days Payable?

FluoroPharma Medical FPMI Days Payable is 0.00 as of Dec. 2016.

FluoroPharma Medical's average Accounts Payable for the three months ended in Dec. 2016 was $1.37 Mil. FluoroPharma Medical's Cost of Goods Sold for the three months ended in Dec. 2016 was $0.00 Mil.

The historical rank and industry rank for FluoroPharma Medical's Days Payable or its related term are showing as below:

FPMI's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 112.84
* Ranked among companies with meaningful Days Payable only.

FluoroPharma Medical's Days Payable stayed the same from Dec. 2015 (0.00) to Dec. 2016 (0.00). stayed the same

FluoroPharma Medical Days Payable Historical Data

* Premium members only.

The historical data trend for FluoroPharma Medical's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

FluoroPharma Medical Days Payable Chart

FluoroPharma Medical Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Days Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FluoroPharma Medical Quarterly Data
Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16
Days Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FPMI vs HSTC, OBMPD, GOVX: Days Payable Comparison

For the Biotechnology subindustry, FluoroPharma Medical's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

FluoroPharma Medical Days Payable vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, FluoroPharma Medical's Days Payable distribution charts can be found below:

* The bar in red indicates where FluoroPharma Medical's Days Payable falls into.


FluoroPharma Medical Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

FluoroPharma Medical's Days Payable for the fiscal year that ended in Dec. 2016 is calculated as

Days Payable (A: Dec. 2016 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Dec. 2015 ) + Accounts Payable (A: Dec. 2016 )) / count ) / Cost of Goods Sold (A: Dec. 2016 )*Days in Period
=( (1.22 + 1.414) / 2 ) / 0*365
=1.317 / 0*365
=N/A

FluoroPharma Medical's Days Payable for the quarter that ended in Dec. 2016 is calculated as:

Days Payable (Q: Dec. 2016 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: Sep. 2016 ) + Accounts Payable (Q: Dec. 2016 )) / count ) / Cost of Goods Sold (Q: Dec. 2016 )*Days in Period
=( (1.323 + 1.414) / 2 ) / 0*365 / 4
=1.3685 / 0*365 / 4
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Days Payable →
What does a Days Payable of 0.00 mean?
FluoroPharma Medical (FPMI) has a Days Payable of 0.00 as of Dec. 2016. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on FluoroPharma Medical and its competitors.
Is FluoroPharma Medical's Days Payable too high?
FluoroPharma Medical's current Days Payable is 0.00.
How does FluoroPharma Medical's Days Payable compare to HSTC and OBMPD?
FluoroPharma Medical's Days Payable of 0.00 can be compared against companies in the Biotechnology industry. The industry median Days Payable is 112.84. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 703 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on FluoroPharma Medical and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. FluoroPharma Medical's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is FluoroPharma Medical stock overvalued right now?
FluoroPharma Medical (FPMI) has a current Days Payable of 0.00. The current Days Payable is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For FluoroPharma Medical (FPMI), the current Days Payable is 0.00 as of Dec. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

FluoroPharma Medical Business Description

Address 701 South Carson Street, Suite 200, Carson City, NV, USA, 89701
FluoroPharma Medical Inc is a us-based biopharmaceutical company. It specializes in developing and commercializing molecular imaging pharmaceuticals with initial applications in the area of cardiology. The company focuses on the development of novel cardiovascular imaging agents which detect and assess acute and chronic forms of coronary artery disease (CAD). The company's clinical-stage molecular imaging pharmaceutical product candidates are 18-F TPP (BFPET) and 18-F FCPHA (CardioPET). The 18-F TPP is designed for use in stress-testing for patients with proven CAD whereas 18-F FCPHA is a molecular imaging agent which is designed to assess myocardial blood flow and metabolism in patients with CAD. The company operates in a single segment being Biopharmaceutical research and development.